

PI	DEPARTMENT	FUNDING AGENCY	PROJECT TITLE	PROJECT BEGIN DATE	PROJECT END DATE	AMOUNT AWARDED	AWARD DATE
PIGOTT T A	PSYCHIATRY	SHIRE PHARMACEUTICAL DEV	A PHASE III, 3 WK,MULTICTR...SAFETY AND EFFICACY STUDY OF EXTENDED-RELEASE CARBAMAZEPINE IN THE TREATMENT OF BIPOLAR..	07/01/2002	10/31/2003	\$7,000.00	12/02/2002
SILVERSTEIN J H	PEDIATRICS	QUINTILES INC	MULTI-CTR,OPN-LBL,OBSERVATIONAL STUDY OF TESTOSTERONE-GEL (1%) IN THE TREATMENT OF ADOLESCENT BOYS WITH HYPOGONADISM	06/21/2002	07/14/2003	\$2,000.00	12/03/2002
LAOS L F	UFHSCJ/MEDICINE	ELI LILLY & COMPANY	PROTOCOL F1K-US-EVBS (SHORT TITLE)	09/01/2002	04/01/2005	\$1,416.00	12/03/2002
MCCARLEY D	CANCER CENTER	LIGAND PHARMACEUTICALS INC	RANDOMIZED PHASE III TRIAL COMPARING TARGRETIN CAPSULES/ CISPLATIN/VINORELBINE V.CISPLATIN/VINORELBINE IN CHEMOTHERAP	04/01/2002	04/03/2003	\$3,562.50	12/04/2002
SCHATZ D A	PEDIATRICS	AVENTIS	MORNING LANTUS...VS. INTERMEDIATE-ACTING INSULIN TWICE DAILY..IN ADOLESCENT TYPE 1 DIABETES..TWO-ARM...	06/10/2002	04/17/2003	\$5,200.00	12/04/2002
SHEA B F	CANCER CENTER	NATL CANCER INST OF CANADA	PHASE III ADJUVANT TRIAL OF SEQUENCED EC+FILGRASTIM+EPOETIN ALFA FOLLOWED BY PACLITAXEL VERSUS SEQUENCED AC FOLLOWED BY	04/15/2002	04/03/2003	\$2,500.00	12/05/2002
KENNEDY L	MEDICINE	PFIZER INC	CLINICAL UTILITY OF AMLODIPINE/ATORVASTAIN TO IMPROVE CONCOMITANT CARDIOVASCULAR RISK...(GEMINI)	08/12/2002	07/29/2003	\$2,900.00	12/05/2002
FORSMARK C E	MEDICINE	TAP PHARMACEUTICALS INC	STUDY TO EVALUATE THE EFFECT OF LANSOPRAZOLE 30MG QD VERSUS ESOMEPRAZOLE 40MG QD ON HEALING AND SYMPTOM RELIEF IN SUBJEC	08/20/2002	04/19/2004	\$15,012.50	12/05/2002

PI	DEPARTMENT	FUNDING AGENCY	PROJECT TITLE	PROJECT BEGIN DATE	PROJECT END DATE	AMOUNT AWARDED	AWARD DATE
GUTHRIE T H	UFHSCJ/MEDICINE	CELGENE CORPORATION	MULTICTR, RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY OFTHE SAFETY AND EFFICACY OF DEXAMETHYLPHENIDATE HYDROCHLORIDE	06/27/2002	03/31/2003	\$1,500.00	12/06/2002
LEWIN A S	MOLECULAR GENETICS & MICROBIO	STEINBACH FOUNDATION	OPTIMIZING AAV-VECTORED GENE THERAPY FOR AMD-ASSOCIATED NEOVASCULARIZATION	07/01/2002	06/30/2005	\$300,000.00	12/06/2002
BLIER P	PSYCHIATRY	ELI LILLY & COMPANY	OPN-LBL TREATMENT WITH DULOXETINE HYDROCHLORIDE ONCE-DAILY DOSING FOR EVAL OF STABILIZATION DOSE IN PATIENTS ....	10/03/2002	08/07/2003	\$13,610.00	12/06/2002
PERRY S J	UFHSCJ/EMERGENCY MEDICINE	NATL PATIENT SAFETY FOUNDATION	TRANSITIONS IN CARE:EMERGENCY DEPARTMENT SIGN-OVERS	01/15/2003	01/14/2004	\$99,995.00	12/06/2002
SPOTNITZ W D	SURGERY	BAXTER HEALTHCARE CORP	PROTOCOL #55003:EVALUATION OF THE TOPICAL HEMOSTATIC EFFICAYAND SAFETY OF FIBRIN SEALANT VAPOR HEATED, SOLVENT/DETERGENT	09/21/2002	09/08/2003	\$5,787.50	12/06/2002
MOREL L M	PATHOLOGY & LABORATORY MED	YALE UNIVERSITY	FUNCTIONAL AND GENETIC ANALYSIS OF INTRINSIC T CELL DEFECTS IN A MOUSE MODEL OF SLE	07/01/2002	06/30/2003	\$10,000.00	12/09/2002
DECERCE J	UFHSCJ/NEUROLOGY	IVAX CORP	EFFICACY AND SAFETY OF TALAMPANEL AS ADJUNCTIVE THERAPY IN PATIENTS WITH PARTIAL SEIZURE: A PHASE II CLINICAL TRIAL	02/15/2002	02/15/2003	\$24,532.00	12/09/2002
BRANTLY M L	MEDICINE	ALPHA ONE FOUNDATION	ALPHA-1 ANTITRYPSIN DEFICIENCY LABORATORY	12/01/2002	12/31/2003	\$152,125.00	12/09/2002

PI	DEPARTMENT	FUNDING AGENCY	PROJECT TITLE	PROJECT BEGIN DATE	PROJECT END DATE	AMOUNT AWARDED	AWARD DATE
BLACKBAND S J	NEUROSCIENCE	DUKE UNIVERSITY	MAGNETIC RESONANCE IMAGING OF GLUTATHIONE IN TUMORS	08/16/2002	07/31/2003	\$27,783.00	12/10/2002
NIZAM M S	MEDICINE	PAREXEL INTERNATIONAL CORP	HOE 901/4033 GOAL A1C	06/11/2002	08/01/2003	\$2,000.00	12/10/2002
XIAO L	CANCER CENTER	FLIGHT ATTENDANT MED RES INST	PKC- EXPRESSION ON THE OUTCOME OF CHEMOTHERAPY	07/01/2002	06/30/2004	\$1,364.91	12/10/2002
MARSH R D	CANCER CENTER	EASTERN COOP ONCOLOGY GROUP	E1201- A RENDOMIZED PHASE II STUDY IN OPERABLE ADENOCARCINOMA OF THE ESOPHAGAS TO MEASURE RESPONSE RATE AND TOXICITY....	12/09/2002	10/16/2003	\$9,875.00	12/10/2002
BABCOCK E T	MEDICINE	PAREXEL INTERNATIONAL CORP	GLYCEMIA OPTIMIZATION WITH ALGORITHMS AND LABS AT POINT OF CARE (GOAL A1C)	05/21/2002	05/17/2003	\$1,000.00	12/11/2002
KAUSHAL S	OPHTHALMOLOGY	HUGHES MEDICAL INST, HOWARD	HHBRSP-SHARED EQUIPMENT	12/15/2002	06/30/2003	\$59,128.03	12/11/2002
MOREL L M	PATHOLOGY & LABORATORY MED	NATL INSTITUTES OF HEALTH	CONGEIC STRAINS: A MODEL FOR GENE/ENVIRONMENT INTERACTIONS	07/15/2002	09/29/2003	\$7,597.28	12/11/2002
MENDENHALL W M	RADIATION ONCOLOGY	AM COLL OF RADIOLOGY	RTOG BR-0118: PHASE III STUDY OF CONVENTIONAL RAD. THRPY PLUS THALIDOMIDE (NSC#66847) VS. CONVENTIONAL RAD. THRPY	01/01/2002	12/31/2007	\$4,400.00	12/11/2002
KERWIN A J	UFHSCJ/SURGERY	ASTRAZENECA	SKIN/SKIN STRUCTURE INFECTIONS	11/20/2002	10/20/2003	\$8,500.00	12/11/2002
LAOS L F	UFHSCJ/MEDICINE	ELI LILLY & COMPANY	PROTOCOL F1K-MC-EVCL (SHORT TITLE)	09/01/2002	04/01/2005	\$4,918.00	12/12/2002
CLARKE L L	HEALTH POLICY & EPIDEMIOLOGY	SARASOTA COUNTY	AGREEMENT BETWEEN SCOPE AND UF FOR COMMUNITY HEALTH PLANNINGSERVICES	10/01/2002	06/30/2003	\$27,508.44	12/12/2002

PI	DEPARTMENT	FUNDING AGENCY	PROJECT TITLE	PROJECT BEGIN DATE	PROJECT END DATE	AMOUNT AWARDED	AWARD DATE
MARSH R D	CANCER CENTER	EASTERN COOP ONCOLOGY GROUP	COOPERATIVE GROUP OUTREACH PROGRAM	07/12/2002	06/30/2003	\$14,115.00	12/13/2002
MARSH R D	CANCER CENTER	EASTERN COOP ONCOLOGY GROUP	COOPERATIVE GROUP OUTREACH PROGRAM	07/12/2002	06/30/2003	\$9,875.00	12/17/2002
WARD JR H E	PSYCHIATRY	STANFORD UNIVERSITY	PULSE LOADED I.V. CLOMIPRAMINE IN UNRESPONSIVE OCD	04/01/2001	03/31/2002	\$156,739.00	12/18/2002
BRANTLY M L	MEDICINE	ALPHA ONE FOUNDATION	GENETIC MODIFIERS OF THE ALPHA 1-ANTITRYPSIN DEFICIENCY	09/30/2001	08/30/2003	\$3,600.00	12/18/2002
MANDEL R J	NEUROSCIENCE	HEREDITARY DISEASE FOUNDATION	RAAV DELIVERY OF BDNF ADN CNTF TO HD MOUSE MODELS	09/01/2002	08/31/2004	\$65,000.00	12/18/2002
KLEIN P A	PATHOLOGY & LABORATORY MED	NATIONAL SCIENCE FOUNDATION	URTD & ENVIRONMENTALLY-THREATENED GOPHER TORTOISES	06/01/2002	05/31/2007	\$9,527.00	12/19/2002
LEWIS S B	NEUROLOGICAL SURGERY	UNIV OF CINCINNATI	FAMILIAL INTRACRANIAL ANEURYSM STUDY, COST REIMBURSEMENT	09/18/2002	07/31/2003	\$19,449.00	12/19/2002
SILLIMAN S L	UFHSCJ/NEUROLOGY	MAYO CLINIC	ISCHEMIC STROKE GENETICS STUDY	07/15/2002	05/31/2003	\$54,608.00	12/20/2002
OBRIEN T W	BIOCHEMISTRY & MOLECULAR BIO	PFIZER INC	EFFECT OF OXAZOLIDINONES ON MAMMALIAM MITOCHONDRIAL PROTEIN SYNTHESIS	12/17/2002	12/16/2003	\$189,744.00	12/23/2002
JANELLE J W	MEDICINE	CUBIST PHARMACEUTICALS INC	A...COMPARATIVE STUDY OF CIDECEIN...ZYVOX...IN THE TREATMENT OF HOSPITALIZED ADULTS WITH SUSPECTED VANCOMYCIN-RESISTANT..	09/17/2002	07/23/2003	\$6,000.00	12/23/2002
LYNCH JR J W	CANCER CENTER	CHIRON CORPORATION	PHASE, I, DOSE-FINDING STUDY OF RITUXIMAB..FOR RELAPSED AND REFRACTORY NON-HODKIN'S LYMPHOMA	08/12/2002	10/13/2003	\$7,181.00	12/23/2002

PI	DEPARTMENT	FUNDING AGENCY	PROJECT TITLE	PROJECT BEGIN DATE	PROJECT END DATE	AMOUNT AWARDED	AWARD DATE
YANG L	PATHOLOGY & LABORATORY MED	NATL INSTITUTES OF HEALTH	IN VITRO GENERATION OF FUNCTIONAL PANCREATIC ISLET CELLS FROM BONE MARROW-DERIVED PROGENITOR CELLS	01/02/2003	11/30/2004	\$145,000.00	12/23/2002
HUDAK M L	UFHSCJ/PEDIATRICS	CHILDREN'S HOSP - PHILADELPHIA	LOW DOSE INHALED NITRIC OXIDE FOR THE PREVENTION & TREATMENT OF CHRONIC LUNG DISEASE IN THE PRETERM INFANT "NO/CLD STUDY"	03/01/2002	02/28/2003	\$7,500.00	12/26/2002
MOREB J S	CANCER CENTER	BERLEX LABORATORIES	GM-CSF TREATMENT AFTER HIGH-DOSE CHEMOTHERAPY (HDC) AND AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) FOR LYMPHOMA...	10/30/2002	10/29/2003	\$55,000.00	12/26/2002
HAUSWIRTH W W	OPHTHALMOLOGY	FDTN FOR FIGHTING BLINDNESS	DEVELOPING VIRAL VECTORS FOR GENE THERAPY OF CANINE MODELS OF ADRP AND XLRP	09/01/2002	08/31/2005	\$100,000.00	12/27/2002
MOLDAWER L L	SURGERY	ICOS CORPORATION	A PHASE 2...SAFETY AND EFFICACY STUDY OF A RECOMBINANT CHIMERIC MONOCLONAL ANTIBODY AGAINST HUMAN CD14 IN HOSPITALIZED..	06/27/2002	06/27/2003	\$10,625.00	12/30/2002
BICHER G S	CTR FOR CLINICAL TRIALS RES	GLAXO SMITHKLINE	..EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS... SB462795 IN HEALTHY POSTMENOPAUSAL WOMEN	11/20/2002	11/07/2003	\$242,707.50	12/30/2002